NX PharmaGen acquires, develops, and monetizes mature clinical-stage breakthrough technologies.
NX Pharmagen has raised $590K in total funding. The most recent round was Debt Financing. The last funding was announced in October 2022.
NX Pharmagen's investors include Keyhorse Capital.
NX Pharmagen is headquartered in Louisville, United States.
NX PharmaGen acquires, develops, and monetizes mature clinical-stage breakthrough technologies.
NX Pharmagen is at the Debt Financing stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"NX Pharmagen — Funding & Investors." VCBacked, October 21, 2022, https://www.vcbacked.co/company/nx-pharmagen. Accessed September 30, 2026.
VCBacked. (2022). NX Pharmagen — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/nx-pharmagen
{{cite web |title=NX Pharmagen — Funding & Investors |url=https://www.vcbacked.co/company/nx-pharmagen |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated